Q220 reflects the full impact of COVID-19, driving a downward slide in all segments
For Q220, according to BioMedGPS’ SmartTRAK Financial Dashboard, the US Infection Prevention - Vascular Access Adjunct Products market was down -16.8% YoY.
The prevention of Hospital-Acquired Infections (HAIs) continues to drive measures and practices to reduce Central Line-Associated Bloodstream Infections (CLABSIs) and is creating demand for products that can address these issues. Numerous programs and educational tools are being developed to provide measures and strategies that assist healthcare providers in the prevention and reduction of infection in acute care and other settings.
Among the many topics covered in the comprehensive Q220 Infection Prevention: US Vascular Access Adjunct Market Recap* are:- Complete Market Overview with Company Revenues and Shares
- Dressings: Securement and Stabilization of VA Devices
- Antimicrobial Devices
- Antimicrobial IV Skin Preps
- Mechanical Securement Devices
- Q220 News and Highlights
The COVID-19 crisis continues to put the spotlight on infection control within hospitals and further reinforces the importance of the infection preventionist (IP) in the “new normal” healthcare setting. Due to the COVID-19 outbreak and limited resources within acute care hospitals, CMS announced extensions to the HAC Quality programs indicating ...
*The entire article and the links can only be viewed by SmartTRAK subscribers to this module. For more information on how to receive a demo and subscribe, please click the button below.
